IB
International Biotechnology Trust PLC
13F filer · CIK 0000942257Last filed Nov 14, 2023
Inactive · not filing 13F
13F portfolio value$297MU.S. long equity reported on 13F
Positions659 new · 5 closed
Net flow last quarter-$12.9MBuys minus sells
Top 10 positions weight47.8%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q3 2023Reported Nov 14, 202365 positions | |||||
| $21.3M | 7.17% | 0.01% | -32.4% | Q4 2016 | |
| $20.7M | 6.97% | 0.16% | Not reported | Q4 2016 | |
| $17.5M | 5.90% | 0.02% | +61.6% | Q4 2016 | |
| ITITCIIntra-Cellular Therapies, Inc. | $16.5M | 5.57% | 0.33% | +79.7% | Q1 2020 |
| $13.6M | 4.58% | 0.08% | +162.0% | Q4 2016 | |
| $11.8M | 3.96% | 0.79% | -18.5% | Q1 2017 | |
| $10.4M | 3.50% | 1.71% | -22.2% | Q4 2021 | |
| $10.3M | 3.48% | 0.03% | +265.5% | Q4 2016 | |
| $10.3M | 3.47% | 0.54% | -44.9% | Q2 2021 | |
| MTMRTXMirati Therapeutics, Inc. | $9.4M | 3.17% | 0.31% | -16.9% | Q1 2019 |
| $8.91M | 3.00% | 0.35% | +212.4% | Q1 2018 | |
| $8.33M | 2.81% | 2.60% | +7909.7% | Q2 2019 | |
| $8.07M | 2.72% | 0.72% | +81.4% | Q3 2020 | |
| $7.66M | 2.58% | 0.07% | -35.6% | Q1 2021 | |
| $7.3M | 2.46% | 0.01% | Not reported | Q4 2016 | |
| $7.28M | 2.45% | 0.01% | -67.2% | Q4 2016 | |
| $6.93M | 2.34% | 0.03% | Not reported | Q4 2016 | |
| $6.52M | 2.20% | 0.03% | -54.9% | Q3 2017 | |
| $5.4M | 1.82% | 0.44% | +1080.0% | Q2 2023 | |
| $5.34M | 1.80% | 0.16% | +0.3% | Q4 2021 | |
| KTKRTXKaruna Therapeutics, Inc. | $5.16M | 1.74% | 0.08% | +18.7% | Q2 2022 |
| $4.07M | 1.37% | 0.12% | Not reported | Q4 2020 | |
| $3.79M | 1.28% | 1.28% | +35.1% | Q1 2023 | |
| $3.74M | 1.26% | 0.11% | +19.0% | Q4 2016 | |
| RTRVNCRevance Therapeutics, Inc. | $3.31M | 1.11% | 0.33% | Not reported | Q3 2022 |
| $3.25M | 1.09% | 0.03% | -58.1% | Q4 2016 | |
| $3.23M | 1.09% | 0.03% | +42.0% | Q4 2016 | |
| $3.19M | 1.08% | 0.17% | Not reported | Q3 2021 | |
| $3.17M | 1.07% | 0.11% | -18.1% | Q4 2021 | |
| $3.15M | 1.06% | Not reported | Not reported | Q4 2022 | |
| $3.12M | 1.05% | 0.14% | +258.8% | Q2 2021 | |
| $2.86M | 0.96% | 0.08% | Not reported | Q4 2019 | |
| $2.67M | 0.90% | 0.10% | Not reported | Q4 2017 | |
| $2.55M | 0.86% | 0.01% | Not reported | Q3 2021 | |
| $2.38M | 0.80% | 0.05% | -34.9% | Q4 2016 | |
| MPMRNSMarinus Pharmaceuticals, Inc. | $2.34M | 0.79% | 0.53% | +222.2% | Q2 2023 |
| $2.28M | 0.77% | 0.00% | +46.0% | Q1 2017 | |
| $2.23M | 0.75% | 0.03% | Not reported | Q4 2016 | |
| $2.13M | 0.72% | 0.14% | Not reported | Q3 2022 | |
| $2.02M | 0.68% | 0.17% | +584.6% | Q2 2019 | |
| $1.95M | 0.66% | 0.03% | Not reported | Q1 2017 | |
| $1.92M | 0.65% | 0.01% | Not reported | Q2 2021 | |
| $1.56M | 0.53% | Not reported | Not reported | Q2 2022 | |
| $1.32M | 0.45% | 0.10% | Not reported | Q2 2023 | |
| $1.31M | 0.44% | 0.16% | New | Q3 2023 | |
| $1.23M | 0.41% | 0.22% | -54.2% | Q1 2021 | |
| $1.19M | 0.40% | 0.07% | +131.3% | Q4 2019 | |
| ATFOLDAmicus Therapeutics, Inc. | $1.09M | 0.37% | 0.03% | Not reported | Q4 2016 |
| $1.09M | 0.37% | 0.04% | Not reported | Q3 2020 | |
| $1.08M | 0.36% | 0.03% | Not reported | Q2 2021 | |
| Q2 2023Reported Aug 8, 202361 positions | |||||
| $26M | 7.92% | 0.02% | +28.5% | Q4 2016 | |
| $22.3M | 6.79% | 0.16% | +28.5% | Q4 2016 | |
| $20.1M | 6.11% | 0.95% | Not reported | Q2 2021 | |
| $19.4M | 5.91% | 0.03% | +141.1% | Q4 2016 | |
| $15.7M | 4.79% | 0.96% | +23.6% | Q1 2017 | |
| $15.6M | 4.76% | 2.20% | -2.7% | Q4 2021 | |
| $15.5M | 4.72% | 0.07% | +75.1% | Q3 2017 | |
| APAPLSApellis Pharmaceuticals, Inc. | $11.8M | 3.60% | 0.11% | +309.2% | Q1 2021 |
| $11.6M | 3.55% | 0.11% | +85.1% | Q1 2021 | |
| ITITCIIntra-Cellular Therapies, Inc. | $11.2M | 3.40% | 0.18% | -31.4% | Q1 2020 |
| $11.1M | 3.39% | 0.01% | +151.1% | Q4 2016 | |
| $9.46M | 2.88% | 0.03% | +90.6% | Q4 2016 | |
| MTMRTXMirati Therapeutics, Inc. | $9.39M | 2.86% | 0.45% | +6.6% | Q1 2019 |
| $7.39M | 2.25% | 0.01% | -36.4% | Q4 2016 | |
| RTRVNCRevance Therapeutics, Inc. | $7.3M | 2.22% | 0.33% | +57.8% | Q3 2022 |
| HTHZNPHorizon Therapeutics Public Ltd Co | $6.89M | 2.10% | 0.03% | Not reported | Q4 2016 |
| $6.77M | 2.06% | 0.59% | +212.7% | Q4 2020 | |
| $6.49M | 1.98% | 0.07% | Not reported | Q4 2016 | |
| KTKRTXKaruna Therapeutics, Inc. | $5.57M | 1.69% | 0.07% | +133.6% | Q2 2022 |
| $5.55M | 1.69% | 0.40% | Not reported | Q3 2020 | |
| $5.54M | 1.69% | 0.14% | +117.2% | Q4 2021 | |
| $5.39M | 1.64% | 0.16% | -24.7% | Q4 2021 | |
| $5.08M | 1.55% | 0.03% | Not reported | Q4 2016 | |
| $4.23M | 1.29% | 0.10% | Not reported | Q4 2017 | |
| $4.19M | 1.27% | 0.12% | Not reported | Q4 2020 | |
| $3.92M | 1.19% | 0.95% | Not reported | Q1 2023 | |
| $3.69M | 1.12% | 0.11% | -69.7% | Q1 2018 | |
| ATAKROAkero Therapeutics, Inc. | $3.66M | 1.11% | 0.14% | New | Q2 2023 |
| $3.62M | 1.10% | 0.09% | -30.1% | Q4 2016 | |
| $3.44M | 1.05% | 0.07% | +109.9% | Q4 2016 | |
| $3.38M | 1.03% | 0.49% | -30.7% | Q1 2021 | |
| $3.13M | 0.95% | 0.01% | -48.6% | Q4 2016 | |
| $3.09M | 0.94% | 0.19% | +147.6% | Q3 2021 | |
| $2.62M | 0.80% | 0.01% | Not reported | Q3 2021 | |
| $2.19M | 0.67% | 0.01% | Not reported | Q2 2021 | |
| $2.15M | 0.66% | 0.02% | Not reported | Q4 2016 | |
| $2.13M | 0.65% | 0.03% | Not reported | Q4 2016 | |
| $1.76M | 0.54% | 0.03% | Not reported | Q1 2017 | |
| $1.74M | 0.53% | 0.18% | Not reported | Q3 2022 | |
| $1.63M | 0.50% | 0.10% | New | Q2 2023 | |
| $1.55M | 0.47% | 0.00% | -61.7% | Q1 2017 | |
| $1.33M | 0.40% | 0.03% | Not reported | Q4 2019 | |
| $1.31M | 0.40% | 0.03% | -51.0% | Q2 2021 | |
| $1.21M | 0.37% | 0.04% | Not reported | Q3 2020 | |
| $982K | 0.30% | 0.04% | Not reported | Q2 2021 | |
| $978K | 0.30% | 0.03% | Not reported | Q4 2021 | |
| MPMRNSMarinus Pharmaceuticals, Inc. | $977K | 0.30% | 0.18% | New | Q2 2023 |
| STSAGESage Therapeutics, Inc. | $939K | 0.29% | 0.03% | Not reported | Q4 2016 |
| $925K | 0.28% | 0.16% | Not reported | Q1 2021 | |
| $845K | 0.26% | 0.03% | Not reported | Q1 2019 | |
| Q1 2023Reported May 18, 202361 positions | |||||
| $22.1M | 6.15% | 0.02% | +461.7% | Q4 2016 | |
| $20.2M | 5.63% | 0.13% | +21.8% | Q4 2016 | |
| $18.6M | 5.20% | 0.95% | +115.7% | Q2 2021 | |
| $16.7M | 4.66% | 0.36% | Not reported | Q1 2019 | |
| $15.3M | 4.28% | 0.78% | +10.4% | Q1 2017 | |
| ITITCIIntra-Cellular Therapies, Inc. | $14M | 3.89% | 0.27% | +16.2% | Q1 2020 |
| $10.6M | 2.95% | 0.37% | +51.7% | Q1 2018 | |
| $10.5M | 2.94% | 0.17% | Not reported | Q4 2016 | |
| $10.4M | 2.90% | 0.01% | Not reported | Q4 2016 | |
| $9.64M | 2.69% | 1.01% | -24.2% | Q2 2019 | |
| $9.33M | 2.60% | 0.04% | +22.6% | Q3 2017 | |
| $9.2M | 2.57% | 0.01% | Not reported | Q4 2016 | |
| MTMRTXMirati Therapeutics, Inc. | $9.07M | 2.53% | 0.42% | Not reported | Q1 2019 |
| $7.81M | 2.18% | 0.01% | Not reported | Q2 2022 | |
| $7.75M | 2.16% | 3.62% | +256.4% | Q4 2021 | |
| $6.38M | 1.78% | 0.06% | +90.0% | Q1 2021 | |
| $6.28M | 1.75% | 0.40% | Not reported | Q3 2020 | |
| $6.16M | 1.72% | 0.02% | -43.0% | Q4 2016 | |
| $5.95M | 1.66% | 0.01% | Not reported | Q4 2016 | |
| RTRVNCRevance Therapeutics, Inc. | $5.89M | 1.64% | 0.22% | +52.5% | Q3 2022 |
| $5.7M | 1.59% | 0.03% | +34.4% | Q4 2016 | |
| $4.99M | 1.39% | 0.74% | -32.3% | Q1 2021 | |
| $4.89M | 1.37% | 0.00% | +44.6% | Q1 2017 | |
| $4.88M | 1.36% | 0.24% | +35.6% | Q4 2021 | |
| $4.78M | 1.33% | 0.00% | Not reported | Q4 2016 | |
| $4.51M | 1.26% | Not reported | Not reported | Q4 2022 | |
| $4.5M | 1.26% | 0.13% | -35.4% | Q1 2019 | |
| $4.28M | 1.19% | 0.95% | New | Q1 2023 | |
| $4.06M | 1.13% | 0.13% | +116.0% | Q4 2016 | |
| $3.32M | 0.93% | Not reported | Not reported | Q2 2022 | |
| $3.17M | 0.88% | 0.19% | -62.8% | Q4 2020 | |
| $3.15M | 0.88% | 0.05% | Not reported | Q1 2019 | |
| $2.63M | 0.73% | 0.01% | Not reported | Q2 2021 | |
| $2.51M | 0.70% | 0.03% | Not reported | Q4 2016 | |
| $2.43M | 0.68% | 0.75% | +77.6% | Q2 2022 | |
| APAPLSApellis Pharmaceuticals, Inc. | $2.09M | 0.58% | 0.03% | Not reported | Q1 2021 |
| KTKRTXKaruna Therapeutics, Inc. | $2M | 0.56% | 0.03% | Not reported | Q2 2022 |
| $1.99M | 0.56% | 0.06% | +127.8% | Q4 2021 | |
| $1.92M | 0.54% | 0.03% | Not reported | Q4 2019 | |
| $1.83M | 0.51% | 0.01% | Not reported | Q3 2021 | |
| $1.75M | 0.49% | 0.07% | Not reported | Q2 2021 | |
| $1.74M | 0.48% | 0.03% | Not reported | Q4 2016 | |
| $1.62M | 0.45% | 0.18% | Not reported | Q3 2022 | |
| $1.55M | 0.43% | 0.04% | Not reported | Q4 2019 | |
| $1.54M | 0.43% | 0.03% | Not reported | Q1 2017 | |
| $1.08M | 0.30% | 0.08% | Not reported | Q3 2021 | |
| $1.07M | 0.30% | 0.16% | Not reported | Q1 2021 | |
| $925K | 0.26% | 0.15% | Not reported | Q2 2022 | |
| $912K | 0.25% | 0.04% | Not reported | Q2 2021 | |
| $894K | 0.25% | 0.03% | Not reported | Q4 2021 | |
| Q4 2022Reported Feb 1, 202360 positions | |||||
| HTHZNPHorizon Therapeutics Public Ltd Co | $35.8M | 11.07% | 0.14% | -30.8% | Q4 2016 |
| $18.4M | 5.68% | 0.10% | -20.8% | Q4 2016 | |
| $15.5M | 4.78% | 0.36% | Not reported | Q1 2019 | |
| $14.6M | 4.50% | 0.44% | Not reported | Q2 2021 | |
| $14.3M | 4.42% | 1.34% | +16.0% | Q2 2019 | |
| $13.7M | 4.22% | 0.71% | +28.9% | Q1 2017 | |
| ITITCIIntra-Cellular Therapies, Inc. | $11.7M | 3.62% | 0.23% | Not reported | Q1 2020 |
| MTMRTXMirati Therapeutics, Inc. | $11.1M | 3.41% | 0.42% | +79.4% | Q1 2019 |
| $9.4M | 2.90% | 0.03% | +86.0% | Q4 2016 | |
| $9.02M | 2.79% | 0.03% | Not reported | Q3 2017 | |
| $8.71M | 2.69% | 0.17% | Not reported | Q4 2016 | |
| $8.08M | 2.50% | 0.01% | Not reported | Q4 2016 | |
| $8.06M | 2.49% | 0.25% | Not reported | Q1 2018 | |
| $7.96M | 2.46% | 0.59% | +103.8% | Q4 2020 | |
| $7.42M | 2.29% | 1.15% | +83.1% | Q1 2021 | |
| $6.94M | 2.14% | 0.01% | Not reported | Q2 2022 | |
| $5.92M | 1.83% | 0.01% | -53.0% | Q4 2016 | |
| $5.49M | 1.70% | 0.20% | +585.7% | Q1 2019 | |
| $5.43M | 1.68% | 1.02% | Not reported | Q4 2021 | |
| $4.94M | 1.53% | 0.00% | -72.4% | Q4 2016 | |
| $4.51M | 1.39% | 0.02% | -25.6% | Q4 2016 | |
| $4.41M | 1.36% | Not reported | New | Q4 2022 | |
| $4.27M | 1.32% | 0.00% | Not reported | Q4 2016 | |
| $4.17M | 1.29% | 0.03% | Not reported | Q1 2021 | |
| $3.59M | 1.11% | 0.05% | Not reported | Q1 2019 | |
| $3.56M | 1.10% | 0.17% | Not reported | Q4 2021 | |
| $3.45M | 1.07% | 0.00% | Not reported | Q1 2017 | |
| $2.74M | 0.85% | 0.03% | Not reported | Q4 2016 | |
| $2.48M | 0.77% | 0.40% | Not reported | Q3 2020 | |
| $2.42M | 0.75% | 0.01% | Not reported | Q2 2021 | |
| $2.34M | 0.72% | 0.03% | Not reported | Q4 2019 | |
| RTRVNCRevance Therapeutics, Inc. | $2.21M | 0.68% | 0.15% | Not reported | Q3 2022 |
| $2.02M | 0.63% | 0.07% | Not reported | Q2 2021 | |
| $1.98M | 0.61% | 0.23% | Not reported | Q3 2021 | |
| $1.89M | 0.59% | 0.01% | Not reported | Q3 2021 | |
| APAPLSApellis Pharmaceuticals, Inc. | $1.64M | 0.51% | 0.03% | Not reported | Q1 2021 |
| $1.62M | 0.50% | 0.42% | Not reported | Q2 2022 | |
| $1.59M | 0.49% | 0.06% | Not reported | Q4 2016 | |
| $1.41M | 0.44% | 0.37% | Not reported | Q4 2021 | |
| $1.39M | 0.43% | 0.04% | Not reported | Q4 2019 | |
| $1.38M | 0.43% | 0.36% | Not reported | Q3 2022 | |
| $1.36M | 0.42% | 0.15% | Not reported | Q2 2022 | |
| $1.31M | 0.41% | 0.18% | +632.2% | Q3 2022 | |
| $1.29M | 0.40% | 0.16% | -38.8% | Q1 2021 | |
| $1.23M | 0.38% | 0.08% | Not reported | Q3 2021 | |
| CPCNCEConcert Pharmaceuticals, Inc. | $1.17M | 0.36% | 0.42% | Not reported | Q2 2019 |
| $1.06M | 0.33% | 0.03% | Not reported | Q4 2021 | |
| $1M | 0.31% | 0.04% | Not reported | Q2 2021 | |
| $1M | 0.31% | 0.01% | Not reported | Q2 2021 | |
| $919K | 0.28% | 0.03% | Not reported | Q2 2022 | |
Premium opens every quarter this fund has filed